These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38102573)

  • 61. Potential role of the gut microbiota in neuromyelitis optica spectrum disorder: Implication for intervention.
    Cui C; Ruan Y; Qiu W
    J Clin Neurosci; 2020 Dec; 82(Pt B):193-199. PubMed ID: 33257156
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Overlap syndrome of anti-aquaporin-4 positive neuromyelitis optica spectrum disorder and systemic lupus erythematosus: A systematic review of individual patient data.
    Kopp CR; Prasad CB; Naidu S; Sharma V; Misra DP; Agarwal V; Sharma A
    Lupus; 2023 Sep; 32(10):1164-1172. PubMed ID: 37487596
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of early using azathioprine in the acute phase in neuromyelitis optica spectrum disorder.
    Lin J; Xue B; Chen Z; Huang X; Pang W; Quan W; Huang Y; Li X; Xia J
    Int J Neurosci; 2017 Jun; 127(6):508-515. PubMed ID: 27323840
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: A systematic review and network meta-analysis.
    Huang W; Wang L; Zhang B; Zhou L; Zhang T; Quan C
    Mult Scler Relat Disord; 2019 Oct; 35():246-252. PubMed ID: 31425902
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders.
    Lim YM; Kim H; Lee EJ; Kim HW; Kim HJ; Kim KK
    Mult Scler Relat Disord; 2020 Jul; 42():102109. PubMed ID: 32387973
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders.
    Fragomeni MO; Bichuetti DB; Oliveira EML
    Mult Scler Relat Disord; 2018 Oct; 25():138-142. PubMed ID: 30075406
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Treatment and new evidences in neuromyelitis optica spectrum disorder].
    Illés Z
    Ideggyogy Sz; 2021 Sep; 74(9-10):309-321. PubMed ID: 34657404
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Mycophenolate Mofetil Acute Renal Rejection Study Group
    Transplantation; 2001 Apr; 71(8):1091-7. PubMed ID: 11374408
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab.
    Kim W; Kim SH; Huh SY; Kong SY; Choi YJ; Cheong HJ; Kim HJ
    Eur J Neurol; 2013 Jun; 20(6):975-80. PubMed ID: 23521577
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis.
    Sahin GM; Sahin S; Kiziltas S; Masatlioglu S; Oguz F; Ergin H
    Ren Fail; 2008; 30(9):865-9. PubMed ID: 18925525
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK.
    Elsone L; Kitley J; Luppe S; Lythgoe D; Mutch K; Jacob S; Brown R; Moss K; McNeillis B; Goh YY; Leite MI; Robertson N; Palace J; Jacob A
    Mult Scler; 2014 Oct; 20(11):1533-40. PubMed ID: 24647557
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Association between infections, the microbiome, vaccination, and neuromyelitis optica spectrum disorder.
    Carnero Contentti E; Correale J
    Mult Scler; 2023 Apr; 29(4-5):492-501. PubMed ID: 35903896
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sjögren's syndrome and neuromyelitis optica spectrum disorders (NMOSD)--a case report and review of literature.
    Jayarangaiah A; Sehgal R; Epperla N
    BMC Neurol; 2014 Oct; 14():200. PubMed ID: 25291981
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Neuromyelitis Optica Spectrum Disorders in Africa: A Systematic Review.
    Musubire AK; Derdelinckx J; Reynders T; Meya DB; Bohjanen PR; Cras P; Willekens B
    Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34663674
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Treatment of neuromyelitis optica spectrum disorders.
    Romeo AR; Segal BM
    Curr Opin Rheumatol; 2019 May; 31(3):250-255. PubMed ID: 30920972
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders.
    Mealy MA; Kim SH; Schmidt F; López R; Jimenez Arango JA; Paul F; Wingerchuk DM; Greenberg BM; Kim HJ; Levy M
    Mult Scler; 2018 Nov; 24(13):1737-1742. PubMed ID: 28857723
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Neuromyelitis optica spectrum disorder complicated with Sjögren's syndrome: first pediatric case responsive to mycophenolate mofetil treatment.
    Fang GL; Fang W; Zheng Y; Zhang YX
    Acta Neurol Belg; 2021 Aug; 121(4):1065-1067. PubMed ID: 33136271
    [No Abstract]   [Full Text] [Related]  

  • 79. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.
    Mealy MA; Wingerchuk DM; Palace J; Greenberg BM; Levy M
    JAMA Neurol; 2014 Mar; 71(3):324-30. PubMed ID: 24445513
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Multiple sclerosis and neuromyelitis optica spectrum disorder testing and treatment availability in Latin America.
    Rojas JI; Gracia F; Patrucco L; Alonso R; Carnero Contentti E; Cristiano E
    Neurol Res; 2021 Dec; 43(12):1081-1086. PubMed ID: 34240685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.